



Cancer Science and Targeted Therapy Conference

September 21-23, 2020

Venue

Mantra Bell City

215 Bell Street, Preston

VIC 3072, Australia

Conference Introduction

Session-1 Chemoresistance

To Trick a Transporter: Targeting Lysosomal P-glycoprotein with Innovative Multi-functional Anti-tumour Agents

Des R. Richardson, University of Sydney, New South Wales, Australia

Cancer Chemoresistance and ABC Drug Transporters

Suresh V. Ambudkar, NCI/NIH, MD, USA

Why do we need to know where drugs bind on P-gp?

Richard Callaghan, The Australian National University, Canberra, Australia

Keynote Talks

Targeting Stromal-Tumour Interactions in Pancreatic Cancer – An Effective Therapeutic Approach?

Minoti Apte, South Western Sydney Clinical School, Liverpool, Australia

Mechanism of Enhancing the Response to Checkpoint Inhibitors without Increasing Toxicity

Angus Dalglish, St George's, University of London, UK

Coffee Break

Session-2 Growth Factor Signalling

TGFBR2 Mediated Phosphorylation of BUB1 at Ser-318 is Required for Transforming Growth Factor-B Signaling

Shyam Nyati, University of Michigan, MI, USA

c-Met Activation Leads to the Establishment of a TGFβ-receptor Regulatory Network Required for Bladder Cancer Invasion

Pieter Eichhorn, Curtin University, Perth, Australia

Targeting Protein Synthesis and Growth Signalling in Prostate Cancer

Luc Furic, Monash University, Melbourne, Australia

The TWEAK/Fn14 Pathway as a Therapeutic Target in Hepatocellular Carcinoma and Cholangiocarcinoma

Nina Tirnitz-Parker, Curtin Health Innovation Research Institute, Perth, Australia

Sensitivity of EGFR/HER-2 Positive Cells Isolated from Ascitic Fluid of Advanced Ovarian Cancer Patients to EGFR/HER-2 Inhibitors

Kenny Chitcholtan, University of Otago, Christchurch, New Zealand

Lunch Break

Session-3**Lipid Signalling**

Targeting Sphingolipid Metabolism in Acute Myeloid Leukemia

Stuart Pitson, University of South Australia and SA Pathology, Adelaide, Australia

Regulation of Phosphoinositide 3-kinase Signaling in Breast Cancer

Christina Mitchell, Monash University, Melbourne, Australia

Class II Phosphoinositide 3-kinase β and Cancer: A Novel Therapeutic Target?

Tania Maffucci, Queen Mary University of London, UK

Characterising Roles of the PTEN-PI3K Axis in Breast Tumorigenesis

Antonella Papa, Monash University, Melbourne, Australia

Identifying Optimal Strategies to Target S1P Signaling for the Attenuation of Cancer Progression and Chemotherapeutic Toxicity

Deron R. Herr, National University of Singapore, Singapore

Session-4**Extracellular Vesicles**

Remote Control of Neuroblastoma Metabolism, Proliferation and Gene Expression through MYCN-Regulated Extracellular Vesicles

Arturo Sala, Brunel University London, UK

Pancreatic Cancer: Perspectives for a Brighter Prognosis

Marco Falasca, Curtin University, Perth, Australia

Exosomes Orchestrate Fibroblast-led Cancer Invasion – New Insights into Cancer Signalling

David Greening, Baker Heart and Diabetes Institute, Melbourne, Australia

Poster Presentations

- P-01** **Prognostic and Genetic Features of Multiple Primary Cancers of Esophageal Cancer**
Pei-Wen Yang, National Taiwan University College of Medicine, Taiwan
- P-02** **UBXN2A Inhibits Tumor Invasion and Metastasis by Targeting the MTORC2/AKT Signaling Pathway**
Sanam Sane, University of South Dakota, SD, USA
- P-03** **Metabolic Reprogramming as a Therapeutic Target of Pancreatic Cancer**
Wen-Chun Hung, National Health Research Institutes, Taiwan
- P-04** **A Multicenter Study of the Impact of Body Mass Index on the incidence of Pathologic Complete Response Among Saudi Patients with locally advanced Breast cancer post Neoadjuvant Chemotherapy**
Arwa Abdelmogod, Prince of Wales Hospital, Australia
- P-05** **Association of Age with Clinical Subtypes of Depression Symptoms in Breast Cancer Patients: A Latent Class Analysis**
Yanyan Li, Shandong University, China
- P-06** **Early Detection of Intrahepatic Cholangiocarcinoma**
Magdalena Sejka, The Royal Melbourne Hospital, Melbourne, Australia
- P-07** **Longitudinal Association of Subjective Prospective and Retrospective Memory and Depression among Patients with Glioma**
Xuan Zhang, Shandong University, China

Session-5 **Novel Therapeutics Target in Cancer**

Restoration of Tumour Suppression to Treat wt and Mutant p53 Hormone Related Cancers

Ygal Haupt, Peter MacCallum Cancer Centre, Melbourne, Australia

Functional Genomic Approaches to Identify new Wnt/ β -catenin Regulators in Colorectal Cancer

Ron Firestein, Director, Cancer Centre at Hudson Institute, Monash University, Melbourne, Australia

Ophiobolin A: A Promising Antiglioblastoma Agent

Alexander Kornienko, Texas State University, TX, USA

Targeting the MTORC2 Pathway in Obesity-Associated Colorectal Cancer

Khosrow Rezvani, University of South Dakota, SD, USA

Investigation of miRNA and mRNA Co-expression Network in Ependymoma

Tao Huang, Chinese Academy of Sciences, China

Coffee Break

Session-6 **Cancer Immunotherapy**

Immune Landscape Sculptured by the Peritoneal Microenvironment that supports Metastases arising from Colorectal Primary Tumours

Robert G. Ramsay, Peter MacCallum Cancer Centre, Melbourne, Australia

Immunotherapy of Solid Tumor with the Third Generation TCR-T

Yi Li, Guangzhou Institutes of Biomedicine and Health, China

Deciphering the Role of CD70/CD27 in Oncology

Julie Jacobs, Scientist, Argenx Inc., Belgium

Cancer Immunotherapy by Targeting TGF- β /Smad3

Guangyu Lian, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong

Distribution and Functions of CD39+ $\Gamma\delta$ Tregs Infiltrated in the Microenvironment of Left/Right-Sided Colorectal Cancer

Zhan Yang, Tianjin Medical University Cancer Institute and Hospital, China

Lunch Break

Session-7**Tumor Microenvironment and Cancer Stem Cells**

Novel Nanomedicine Shuts Down Metabolic Cellular Cross-talk Which Reduces Fibrosis and Pancreatic Tumour Progression

Phoebe Phillips, Prince of Wales Clinical School, UNSW Medicine NSW, Australia

Targeting Cell-Cell Communication in Tumours and the Tumour Microenvironment

Peter Janes, Olivia Newton-John Cancer Research Institute, Heidelberg, Australia

Proteomic Profiling of the Prostate Tumour Microenvironment Reveals LOXL2 as a Therapeutic Target

Natalie Lister, Monash University, Melbourne, Australia

The Prognostic Value of S100A10 in Cancer

Normastuti Adhini Tanty, Indonesia International Institute for Life Sciences, Indonesia

Coffee Break

Session-8**Cancer Targeted Therapy**

Regulation of the Hypoxia Transcription Factors by Ascorbate and Potential Implications for Cancer Patients

Gabi Dachs, University of Otago, Christchurch, New Zealand

Repurposing Flubendazole as a Small Molecule Inhibitor of Programmed Cell Death Protein-1

Levon M. Khachigian, University of New South Wales, Sydney, Australia

Discovery of Novel Targetable Pathways and Drug Molecules for Infant Acute Lymphoblastic Leukaemia

Klaartje Somers, Children's Cancer Institute, Sydney, Australia

EDNRB Isoform 3 Confers Temozolomide Resistance in Human Melanoma Cells by Modulating Membrane Potential, Reactive Oxygen Species and Mitochondrial Ca²⁺

Long Cui, Guangzhou Women and Children's Medical and The Chinese University of Hong Kong, Hong Kong

Longitudinal Association of Subjective Prospective and Retrospective Memory and Depression among Patients with Glioma

Xuan Zhang, Shandong University, China

Poster Presentations

Session-9

Cancer Genetics

SMAD Proteins Directly Suppress PAX2 Transcription Downstream of Transforming Growth Factor Beta 1 Signalling in Renal Cell Carcinoma

Michael Eccles, University of Otago, Christchurch, New Zealand

Pharmacologically Targetable Vulnerability in Prostate Cancer Carrying RB1-SUCLA2 Deletion

Chiaki Takahashi, Cancer Research Institute, Kanazawa University, Japan

High Methylation of ZNF582/PAX1 in Cervical Cancer Affected Radio-chemo and Neoadjuvant Chemotherapy Sensitivity and Prognosis

Yuligh Liou, Xiangya Medical Laboratory, Central South University, China

Clinical Application of Tube-chip Digital PCR for Accurate Detection of Gene Mutation in Cancer Patients

Xiwen Jiang, DAAN Gene Co., Ltd. of Sun Yat-sen University, China

Conference Secretariat

Prism Scientific Services Pty Ltd

Level 14, 380 St Kilda Road, Melbourne, VIC 3004, Australia

Tel: +61 383 913 150

Email: manager@cancertherapyconference.com

Web: <https://www.cancertherapyconference.com/>